1.The Effect of Aspirin Alone or Aspirin Plus Additional Antiplatelets Therapy on Upper Gastrointestinal Hemorrhage.
Suh Eun BAE ; Seong Eun KIM ; Sung Ae JUNG ; So Yoon YOON ; Ki Nam SHIM ; Hye Kyung JUNG ; Tae Hun KIM ; Kwon YOO ; Il Hwan MOON
The Korean Journal of Gastroenterology 2011;57(4):213-220
BACKGROUND/AIMS: The increasing incidence of cardiovascular disease has led to an increase in the frequency of upper gastrointestinal (GI) hemorrhage due to the use of antiplatelet agents. This study examined the clinical characteristics of patients with upper GI hemorrhage who were administered aspirin alone or a combination treatment of antiplatelet agents. METHODS: A 656 patients who underwent drug-eluting coronary stenting at Ewha Mokdong Hospital in 2008 were divided into three groups according to the antiplatetlet agents used after the intervention; groups of aspirin alone, aspirin plus clopidogrel, and aspirin, and clopidogrel plus another antiplatelet agent, respectively. Patients admitted with GI hemorrhage in the same period without a medication history of antiplatelet or nonsteroidal anti-inflammatory drugs were used as the control hemorrhage group. The medical records were reviewed. RESULTS: Significant GI symptoms were observed in 21.1% of total patients, of whom 48.2% had ulcers. The upper GI hemorrhage rate was 3.8%. There was no significant difference in the hemorrhage rate between three groups. Compared to the control hemorrhage group, the endoscopic variables of the antiplatelet-related hemorrhage group were not significantly different. However, the Helicobacter pylori infection rate was lower, the admission period was longer, and the mortality rate was higher in the antiplatelet-related hemorrhage group (p<0.05, respectively). There was no direct association between restarting or discontinuance of antiplatelets after the hemorrhage event and mortality. CONCLUSIONS: Adding other antiplatelet agents to aspirin did not increase the hemorrhage rate. However, active diagnostic and therapeutic efforts are recommended in patients with GI symptoms during antiplatelet therapy.
Aged
;
Aspirin/*adverse effects/therapeutic use
;
Cardiovascular Diseases/prevention & control
;
Drug Therapy, Combination
;
Drug-Eluting Stents
;
Endoscopy, Gastrointestinal
;
Female
;
Gastrointestinal Hemorrhage/*chemically induced/mortality/prevention & control
;
Helicobacter Infections/complications/epidemiology
;
Helicobacter pylori
;
Humans
;
Male
;
Middle Aged
;
Peptic Ulcer/complications/epidemiology
;
Platelet Aggregation Inhibitors/*adverse effects/therapeutic use
;
Retrospective Studies
;
Risk Factors
;
Ticlopidine/adverse effects/analogs & derivatives/therapeutic use
2.Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience.
Muhammed SHERID ; Humberto SIFUENTES ; Samian SULAIMAN ; Salih SAMO ; Husein HUSEIN ; Ruth TUPPER ; Charles SPURR ; Subbaramiah SRIDHAR
The Korean Journal of Gastroenterology 2015;65(4):205-214
BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran. METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals. RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for < or =100 days had a higher incidence of GI bleeding than those who were on it for >100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for < or =100 days was 8.2 times higher compared to those who were on the drug for >100 days. The incidence of GI bleeding in patients >65 years old was higher than in those <65 years old (p=0.0453, OR=3). History of previous GI bleeding was another risk factor for GI bleeding in the dabigatran group (p=0.036, OR=6.3). The lower GI tract was the most common site for GI bleeding in the dabigatran group (80.0% vs. 38.1%, p=0.014). CONCLUSIONS: The risk of GI bleeding was lower with dabigatran. The risk factors for GI bleeding with dabigtran were the first 100 days, age >65 years, and a history of previous GI bleeding.
Age Factors
;
Aged
;
Aged, 80 and over
;
Anticoagulants/*adverse effects/therapeutic use
;
Atrial Fibrillation/drug therapy
;
Dabigatran/*adverse effects/therapeutic use
;
Female
;
Gastrointestinal Hemorrhage/*chemically induced/epidemiology/mortality
;
Humans
;
Incidence
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Retrospective Studies
;
Risk Factors
;
Warfarin/*adverse effects/therapeutic use